Warhound Secures $200M to Produce Genetically Engineered Military Working Dogs

Warhound announced its emergence from stealth on Thursday with a $200 million financing round that values the company at $1.2 billion. The capital, led by In-Q-Tel, Sequoia and 8VC, will fund the development of genetically engineered working dogs designed for the U.S. military, law-enforcement and other emergency-response teams.

The move addresses a growing shortfall in the United States’ supply of trained canines. More than 80 percent of the working dogs currently used by the U.S. military are sourced from Europe, and fewer than half of those animals meet the fitness standards required for service. The reliance on foreign-bred dogs, combined with high attrition rates during training, has left a gap that Warhound hopes to fill.

Warhound was co-founded by Ben Lamm, the chief executive of Colossal Biosciences, and Palmer Luckey, co-founder of defense technology firm Anduril. Lamm said he first met Luckey at a conference about a year ago, where Luckey raised the idea of improving the nation’s working-dog program. Subsequent research revealed that many dogs fail training because of genetic predispositions to poor eyesight, cancer, hip dysplasia or muscle atrophy.

To create a new class of canine, Warhound is building a biobank of cell lines from the two breeds most commonly used in military work, the Belgian Malinois and the German Shepherd. Those cells will be edited to remove genes linked to health problems and to add variants that enhance speed, agility, longevity and olfactory capability. The goal is to produce dogs that are both healthier and more capable of tasks such as bomb detection and search operations.

Anduril’s contribution focuses on hardware and software that augment the dogs and their handlers. Planned accessories include bullet-proof vests equipped with data sensors and protective eye goggles that relay situational information to the handler in real time. Luckey, who is not an equity holder, described the equipment as “on top of the dog, not in the dog,” emphasizing safety for both the animal and the human partner.

Colossal Biosciences retains equity in Warhound and will license its gene-editing platform to the venture. A second Colossal-owned company, Viagen, will handle the cloning process. Viagen’s cloning technology, already used in endangered-species programs, boasts a high success rate and will be employed to produce the first batch of engineered puppies. Those pups are slated to be born early next year, with an expectation that they could enter operational service within two years.

Warhound has not disclosed pricing, but it expects to sell the dogs to the Department of Defense, police departments, fire-rescue agencies and other first-responder organizations. The company says it has briefed multiple government entities about the program, though formal approval processes have not been detailed.

Training and post-service care will be overseen in partnership with the American Humane Society, which will help certify the training regimen. The nonprofit’s Military Working Dog Reunification Program is also being positioned as a retirement pathway for dogs that complete their service.

If Warhound’s approach proves viable, it could reshape how the United States sources and equips its canine assets, reducing dependence on overseas breeders while introducing biotech and sensor technology into a traditionally low-tech field. The venture’s progress will likely spark debate over the ethics of genetically modifying animals for combat and public-safety roles, a conversation that will unfold alongside the dogs’ first deployments.